rawfin.tv
Gilead Sciences to Acquire Ouro Medicines for Up to $2.18 Billion
Top Storiesstocks🟠 Score 8AI Generated

Gilead Sciences to Acquire Ouro Medicines for Up to $2.18 Billion

By rawfin.tv Markets Desk||1 min read|AI-assisted · Methodology

Gilead Sciences has announced its intent to acquire Ouro Medicines, a specialist in autoimmune-disease therapies, for a deal valued at up to $2.18 billion. This strategic acquisition aims to expand Gilead's portfolio in the immunology sector.

GILDBiotechnologyMergers & AcquisitionsHealthcare

Related Articles

Adidas Surges 37% to Record Q3 Profit, Lifts Full-Year Targets

Adidas Surges 37% to Record Q3 Profit, Lifts Full-Year Targets

stocks
EQT to Acquire Cleanaway Waste for $6.5 Billion

EQT to Acquire Cleanaway Waste for $6.5 Billion

stocks
S&P 500 Breaches Key Support as AI Sell-Off Pressures Tech Sector

S&P 500 Breaches Key Support as AI Sell-Off Pressures Tech Sector

stocks
US Chip Stocks Plunge 16% in Longest Losing Streak Since 2008

US Chip Stocks Plunge 16% in Longest Losing Streak Since 2008

stocks